Vestcor Inc Invests $127,000 in Structure Therapeutics Inc. (NASDAQ:GPCR)

Vestcor Inc acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,700 shares of the company’s stock, valued at approximately $127,000.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Structure Therapeutics during the fourth quarter worth approximately $40,000. Assetmark Inc. increased its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Structure Therapeutics by 29.8% during the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock worth $115,000 after acquiring an additional 971 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in Structure Therapeutics during the fourth quarter worth approximately $243,000. 91.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several analyst reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $21.11 on Wednesday. Structure Therapeutics Inc. has a 52-week low of $19.39 and a 52-week high of $62.74. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -28.53 and a beta of -2.37. The stock has a 50 day moving average price of $25.08 and a 200 day moving average price of $32.09.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.